Oslo, Copenhagen, November 29, 2000. Only 1 month after the biotech company Nutri Pharma announced its latest US patent, it is time for the company’s next breakthrough on the world’s largest market. Nutri Pharma has, following a five year process, received approval for another patent in the US. The patent secures the combination of Nutri Pharma’s weight lowering and management products and different antismoking compositions.
- It is with great pleasure that we, within such short time, announce the approval of two patents in the US. These patents have great significance when it comes to strengthen our continued competitive advantages, says Michael Oredsson, CEO of Nutri Pharma.
In the research now being patented, it is proved that a smoker who combines the use of Nutri Pharma’s weightreducing product Nutrilett with an antismoking composition like Nicorette, has a greater chance of actually quit smoking than the smoker just using an antismoking product. After one year, twice as many people quit smoking with the combination than with just an antismoking composition. These findings are so surprising that they are to be published in the British Medical Journal.
Often, weight gain is a problem for the smoker trying to quit, and one of the reasons that he or she does not succeed. Research has shown that approximately 50 per cent women and 30 per cent men are not willing to quit smoking because of the weight gaining. It is therefor very promising that the new Nutri Pharma patent includes weight control when one is trying to quit smoking.
- This new patent further strengthens the competitive advantage of Nutri Pharma’s weight reducing products, says Michael Oredsson.
In the Nordic countries, the product has been a market leader for a long time under the brand name Nutrilett. In the US, the product is called ScanDiet, and in this market Nutri Pharma has been gaining market shares day by day since the introduction last spring.
- Obesity and smoking is not the last health threatening factors Nutri Pharma will attack. Through our own research, and through co-operation with several global companies, we will continue to strengthen our knowledge on prepared soy and how it can be used to minimise the risk of life-style related diseases, says Michael Oredsson.
Nutri Pharma’s previous patent in the US, announced on the first of November this year, covers the company’s special technique of combining soy proteins, fibres, and lipids that can be used for reducing the cholesterol level.
Nutri Pharma is a world leading research and development company focused on how to make use of prepared soy for treatment and prevention of life-style related diseases such as obesity, high cholesterol, and type 2 diabetes. All of these diseases affect the cardiovascular system. For more than ten years, the company has carried out scientific research with several of the leading university hospitals in the world, and the research has been published in 16 scientific articles. The research applies medical principles, and is approved and protected through a long line of patents.